Market research
LWBA.F Mesoblast Limited
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 583M
- P/E ratio
- 0.33
- Analyst target
- 11.7
- Dividend yield
- 0.0%
- Beta
- 2.39
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US5907171046
- Market cap
- 583M
- P/E ratio
- 0.33
- Analyst target
- 11.7
- Dividend yield
- 0.0%
- Beta
- 2.39
About
About Mesoblast Limited
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LWBA.F discussion.
5 years, 5 months ago
Mesoblast Limited is currently in a long term downtrend where the price is trading 22.9% below its 200 day moving average.
From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 57.4.
Mesoblast Limited's total revenue rose by 1.6% to $2M since the same quarter in the previous year.
Its net income has dropped by 4.5% to $-26M since the same quarter in the previous year.
Finally, its free cash flow fell by 1709.3% to $-32M since the same quarter in the previous year.
Based on the above factors, Mesoblast Limited gets an overall score of 2/5.